ARI confirms routing, identifies any missing details, and keeps feasibility conversations moving quickly.
Ophthalmology-Only Clinical Research Network
Ophthalmology trials move faster when the network is built for eyes only.
ARI gives sponsors and CROs one operating relationship across six ophthalmology research sites in California and the Southwest. Experienced PIs, centralized startup systems, diverse patient access, and a seven-day preliminary feasibility readout.
Ophthalmology-only SMO
6 coordinated research sites
48-hour acknowledgement
7-day preliminary feasibility
Includes recommended sites, patient-access view, investigator availability, and startup considerations.
Principal investigator-led programs with top-enrolling status globally across multiple specialty studies.
Ophthalmology-only recruitment and site operations across common, chronic, and specialty eye disease programs.
Clinical focus
Purpose-built for ophthalmology sponsors, not retrofitted from a general site network.
ARI’s model is strongest where protocols need specialty investigators, imaging discipline, disease-specific patient access, and multi-visit retention across western markets.
AMD, geographic atrophy, diabetic eye disease, RVO, inherited retinal disease
Experienced investigators and imaging workflows for chronic retina programs, high-touch follow-up, and longitudinal endpoints.
Cornea, dry eye, ocular surface, refractive and device programs
Procedure-aware site operations for visit-heavy protocols, imaging requirements, and sponsor documentation standards.
Thyroid eye disease, rare disease, pediatric, and complex interventional studies
Centralized feasibility and referral logic help sponsors understand which sites, markets, and investigators fit first.
Sponsor pathway
Everything your internal team needs to move from first review to intake.
ARI keeps the sponsor path simple so clinical operations, medical, and procurement teams can evaluate the network and hand off without losing momentum.
Review the network footprint
Confirm geography, specialty depth, and patient-access logic across California and the Southwest.
Open network reviewDownload the sponsor deck
Use the capabilities PDF for internal circulation while your team validates fit and timeline assumptions.
Get the PDFShare protocol stage and priorities
Send what you have, even early. ARI can review study type, markets, timing, and required procedures.
Start intakeReceive a sponsor-ready readout
ARI returns recommended sites, operational considerations, and next-step follow-up from leadership.
Contact sponsor deskSponsor briefing room
Everything a sponsor team usually needs for the first internal pass.
ARI packages the network story around the questions sponsor teams actually ask first: who owns the relationship, which markets fit, how startup is managed, and what happens after intake.
One sponsor-facing team coordinates six sites instead of six parallel feasibility tracks.
Ophthalmology-rooted investigators support rare disease, pediatric, imaging, and device-heavy programs.
Standardized SOPs, training, and documentation keep activation consistent across the network.
Janelle Gonzalez and Daniel Lemor stay on the sponsor path for quick handoff and escalation.
Internal handoff assets
What your team can circulate right now.
- Capabilities PDF for medical, clinical ops, and procurement review.
- Network page organized around California and Southwest market logic.
- Sponsor intake with a 48-hour acknowledgement and seven-day first-pass review cadence.
- Direct sponsor desk contacts for introductions, timing questions, or internal follow-up.
Network footprint
Six active research sites across California and the Southwest.
Two geographic clusters give sponsors concentrated patient access in high-density western markets, coordinated through one network intake and one sponsor team.
California cluster
Los Angeles, Santa Monica, San Francisco
Major metropolitan research markets with diverse patient populations and strong referral networks across the state.
Los Angeles
Santa Monica
San Francisco
Southwest cluster
Las Vegas, Phoenix, Sun City
Large retirement-age populations with high disease prevalence — particularly valuable for age-related conditions and chronic disease programs.
Las Vegas
Phoenix
Sun City
Single intake, multi-site activation
One feasibility conversation covers all six sites. No redundant sponsor meetings or duplicated startup processes.
30,000+ direct. 350,000+ affiliated.
Internal database of 30,000+ patients with access to 350,000+ through affiliated networks and referral systems.
Phase I–IV. Interventional. Device.
Full-phase capability including complex interventional, rare disease, pediatric, and ophthalmic device trials.
